2.0900 0.00 (0.00%)
After hours: 4:00PM EDT
|Bid||1.9500 x 800|
|Ask||2.0800 x 3000|
|Day's Range||2.0788 - 2.1500|
|52 Week Range||0.6000 - 2.9000|
|Beta (3Y Monthly)||2.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
If you want to know who really controls Curis, Inc. (NASDAQ:CRIS), then you'll have to look at the makeup of its share...
The Lexington, Massachusetts-based company said it had a loss of 30 cents per share. Losses, adjusted to extinguish debt, came to 19 cents per share. The drug developer posted revenue of $2.1 million in ...
It is doubtless a positive to see that the Curis, Inc. (NASDAQ:CRIS) share price has gained some 40% in the last three months. But spare a thought for the long term holders, who have held the stock as it bled value over the la...
The Lexington, Massachusetts-based company said it had a loss of 18 cents per share. The drug developer posted revenue of $2.8 million in the period. For the year, the company reported that its loss narrowed ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...
Thinly traded Curis, Inc. (NASDAQ: CRIS ) shares weremoving notably higher Monday on roughly 35 times their average volume. What Happened Curis announced Monday ahead of the market open that it reached ...
A recent bit of biotech news involving Curis has CRIS stock flying high on Monday.Source: Shutterstock Curis (NASDAQ:CRIS) has announced that it has reached a deal with Oberland Capital Management in connection to Erivedge. This has it offering selling rights for a portion of royalty revenues to the group for $135.70 million.According to Curis, the deal with Oberland Capital Management has it receiving a starting payment of $65.00 million. It is then able to collect additional payments of up to $70.70 million from the company. However, Erivedge must reach certain milestones for CRIS to receive these payments.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe biotech news also includes Curis already making good use of the money from the deal. It notes that it used a portion of the cash from the deal to pay off some of its debts. It is also using the remaining $30 million from the upfront payment to funds its operations."We believe this structure provides Curis with substantial non-dilutive capital today, while retaining significant participation in the future upside potential of Erivedge," James Dentzer, President and CEO of Curis, said in a statement. "The proceeds of this transaction further strengthen our cash position as we fund our three lead therapeutic candidates to reach their near term development catalysts and beyond." * 7 Marijuana Stocks to Play the CBD Trend Erivedge is a drug from Curis that is used to treat patients suffering from Hedgehog signaling due to genetic mutations. The drug does this by targeting a protein called Smoothened.CRIS stock was up 31% as of Monday morning and is up 74% since the start of the year. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Dual-Class Stocks That Will Outperform * 7 Reasons Why Apple Streaming Won't Move the Needle for Apple Stock * 7 A-Rated Stocks to Buy in the Second Quarter As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Biotech News: Why Curis Stock Is Soaring Today appeared first on InvestorPlace.
First Eagle Investment (Trades, Portfolio) Management axed 90.99% of its stake in Curis Inc. (CRIS) on Dec. 31 as the stock hovered near all-time low prices, the New York-based firm disclosed Wednesday. Warning! GuruFocus has detected 3 Warning Signs with CRIS.
Curis (CRIS) delivered earnings and revenue surprises of 29.03% and 19.62%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Lexington, Massachusetts-based company said it had a loss of 22 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
Every investor in Curis Inc (NASDAQ:CRIS) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...